Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28628703 | 0.81 | CYP19A1 (0.38) | — | |
| SCHEMBL9672981 | 0.78 | ACACB (0.40) | CTSLESR1ESR2 | |
| SCHEMBL26936224 | 0.78 | ACACB (0.40) | CTSLESR1ESR2 | |
| SCHEMBL4603880 | 0.78 | TSHR (0.30) | TSHR | |
| SCHEMBL8763089 | 0.77 | ESR2 (0.42) | TSHRESR1ESR2 | |
| SCHEMBL16962399 | 0.74 | NOS2 (0.43) | PGK1PGK2TSHRESR1NR3C1 | |
| SCHEMBL23162729 | 0.74 | ALDH1A1 (0.42) | TSHR | |
| SCHEMBL28147687 | 0.72 | HTR2A (0.42) | CTSSTSHR | |
| SCHEMBL13593628 | 0.71 | SIGMAR1 (0.52) | TSHR | |
| SCHEMBL1752148 | 0.71 | SIGMAR1 (0.52) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080145946-A1 | Impurity of anastrozole intermediate, and uses thereof | PONTIROLI ALESSANDRO | 2008-06-19 | — | — | US | disclosed |
| EP-1896398-A2 | AN IMPURITY OF ANASTROZOLE INTERMEDIATE, AND USES THEREOF | Sicor Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070087441-A1 | Impurity of anastrozole intermediate, and uses thereof | SICOR, INC. | 2007-04-19 | — | — | US | disclosed |
| WO-2007002720-A2 | AN IMPURITY OF ANASTROZOLE INTERMEDIATE, AND USES THEREOF | SICOR, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087441-A1 | Impurity of anastrozole intermediate, and uses thereof | CYP19A1, HSD17B11, SHBG | CTSB 750/4885CTSL 1270/4885CTSS 2119/4885 |
| US-20080145946-A1 | Impurity of anastrozole intermediate, and uses thereof | CYP19A1, HSD17B11, SHBG | CTSB 750/4885CTSL 1270/4885CTSS 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.